Idera Pharmaceuticals has entered into an exclusive worldwide collaboration and license agreement with GSK to research, develop and commercialize selected molecules from Idera’s 3rd generation antisense platform for the treatment of selected targets in renal disease. Idera is eligible to receive approximately $100 million in development and regulatory milestones, including a $2.5 million upfront and royalties on sales.   “We are excited to be working with GSK to apply our drug discovery and...